Latest News

Kidney-protective therapy is now layered. How pharmacists screen, stage by KDIGO, stagger ACE/ARB, SGLT2, GLP-1, and finerenone, and cut CV risk.

CK0803 is an investigational allogeneic cord blood–derived regulatory T-cell therapy designed to target neuroinflammation in amyotrophic lateral sclerosis.

Daraxonrasib, an oral RAS inhibitor, was approved for adults with metastatic pancreatic adenocarcinoma after prior systemic therapy or when multiagent systemic therapy is not appropriate.

New data show Opill reaches uninsured, rural, and younger patients—putting pharmacists at the center of daily dosing counseling.

The FDA has expanded the approval of dolutegravir expands access to a second-generation integrase inhibitor for infants in the neonatal period.

Stacey Cutrell, PharmD, BCACP, CDCES, on the PREVENT calculator, screening for secondary causes, intensive BP targets, and fixing stubborn blood pressure.

Abbott's Libre Duo 10 Day tracks both glucose and ketones to flag rising DKA risk in people with diabetes 2 years and older.

Sunburn and tanning signal DNA damage—learn SPF 30+ sunscreen tips, reapplication, and medication photosensitivity for skin cancer prevention.

The FDA has approved 2 zanidatamab-hrii–based regimens following phase 3 results demonstrating significant improvements in progression-free survival.

Nipocalimab is the first therapy approved specifically for wAIHA, a rare, life-threatening autoantibody disease driving red blood cell destruction.

Tracking 3-year changes in the heart stress marker separated older adults whose risk climbed from those whose risk resolved.

Certifying pharmacy technicians to administer immunizations streamlines workflow, combats vaccine misinformation, and positions pharmacies to fill a coming gap in physician access.

Susan Cornell, PharmD, CDCES, FAPhA, FADCES, explains how pharmacists can spot metabolic dysfunction-associated steatotic liver disease (MASLD) risk, weigh GLP-1 and MASH therapies, and pair medication with lifestyle change.

A lesser-known viral protein may drive both the hyperinflammation and vascular damage seen in severe and long COVID-19.

The FDA has granted fast track designation to ERAS-0015, an investigational oral pan-RAS molecular glue that has shown early antitumor activity in previously treated KRAS G12X pancreatic ductal adenocarcinoma.

The FDA-granted priority review raises the possibility of an immunotherapy-first approach that could allow some patients to avoid chemotherapy, radiation, and surgery.

Novo Nordisk's false-advertising case against Eli Lilly turns on GLP-1 dosing—here's the context pharmacists need when patients ask which drug is better.

Night shift and insomnia may triple long-COVID risk; learn how chronic insomnia and long-COVID links affect health workers and prevention.

The FDA granted fast track designation to safusidenib, an investigational oral IDH1 inhibitor that produced durable responses in a phase 2 study of patients with treatment-naive grade 2 IDH1-mutant glioma.

Given the growing market availability and current underutilization of biosimilars, pharmacists must possess a comprehensive understanding of these agents to effectively advocate for their adoption.

A nationwide study found that Black pregnant patients initiating buprenorphine had a 69% higher adjusted risk of treatment discontinuation during pregnancy than White patients.